Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients with Levodopa-Induced Dyskinesias (the SPLENDID Study)

Clinical Neuropharmacology

Volumn 27, Issue 2, 2004, Pages 58-62

  Olanow, C Warren ^a   Damier, Philippe ^b   Goetz, Christopher G ^c   Mueller, Thomas ^d   Nutt, John ^e   Rascol, Olivier ^f   Serbanescu, Alexandru ^g   Deckers, Frieda ^h   Russ, Hermann ^g  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CHU de Nantes   (France)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d ST JOSEF HOSPITAL   (Germany)

^e Department of Neurology   (United States)

^f CHU PURPAN   (France)

^g CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^h MERCK KGAA   (Germany)

Author keywords

Parkinson disease; Sarizotan; SPLENDID

Indexed keywords

DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; LEVODOPA; SARIZOTAN; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ON OFF PHENOMENON; OPEN STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT;

AGED; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MEDICAL RECORDS; ORGANIC CHEMICALS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 2342450729     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200403000-00003     Document Type: Article

References (13)

1. Schrag A, Quinn NP. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain. 2000;123:2297-2305.
2. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(suppl 5):1-88.
3. Merck Pharmaceutical KGaA. Data on file. Darmstadt, Germany: Merck Pharmaceutical KGaA.
4. Bibbiani F, Oh JD, Chase TN. Sarizotan 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology. 2001;57:1829-1834.
5. Olanow CW, Goetz C, Mueller T, et al. A prospective 3-month multicenter, open label dose-rising study of the effect of Sarizotan on dyskinesia in Parkinson's disease. Mov Disord. 2002;17(suppl. 5):S326.
6. Gibb WK, Lees AJ. The relevance of the Lewy body to the pathogenesis of the idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51:745-752.
7. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al., eds. Recent Developments in Parkinson's Disease. Florham Park: MacMillan Healthcare Information; 1987:153-163.
8. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7:2-13.
9. Goetz CG. Rating scales for dyskinesias in Parkinson's disease. Mov Disord. 1999;14:48-53.
10. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord. 1994;9:990-994.
11. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23:75-81.
12. Clinical Global Impression. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rev. ed. Baltimore, MD: National Institutes of Mental Health; 1976:217-222.
13. Wood IB, Frankland AW, James VHT, et al. A rapid test of adrenocortical function. Lancet. 1965;i:243.